PRTK Paratek Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRTK

Price (delayed)

$1.58

Market cap

$90.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$304.42M

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and ...

Highlights
The gross profit has grown by 21% YoY and by 2.6% from the previous quarter
PRTK's revenue is up by 20% year-on-year and by 4% since the previous quarter
Paratek Pharmaceuticals's equity has decreased by 35% YoY and by 11% from the previous quarter
PRTK's quick ratio is down by 33% YoY and by 17% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://paratekpharma.com
Peers: AGEN RARE

Key stats

What are the main financial stats of PRTK
Market
Shares outstanding
57.28M
Market cap
$90.51M
Enterprise value
$304.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.83
Earnings
Revenue
$166.64M
EBIT
-$47.57M
EBITDA
-$47.17M
Free cash flow
-$35.97M
Per share
EPS
-$1.18
Free cash flow per share
-$0.63
Book value per share
-$3.3
Revenue per share
$2.93
TBVPS
$2.64
Balance sheet
Total assets
$150.83M
Total liabilities
$339.87M
Debt
$259.07M
Equity
-$189.04M
Working capital
$78.27M
Liquidity
Debt to equity
-1.37
Current ratio
3.39
Quick ratio
2.51
Net debt/EBITDA
-4.53
Margins
EBITDA margin
-28.3%
Gross margin
84.5%
Net margin
-39.5%
Operating margin
-29%
Efficiency
Return on assets
-40.8%
Return on equity
N/A
Return on invested capital
-13.7%
Return on capital employed
-40.3%
Return on sales
-28.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTK stock price

How has the Paratek Pharmaceuticals stock price performed over time
Intraday
-2.47%
1 week
-13.19%
1 month
-1.25%
1 year
-11.73%
YTD
-15.51%
QTD
-37.8%

Financial performance

How have Paratek Pharmaceuticals's revenue and profit performed over time
Revenue
$166.64M
Gross profit
$140.84M
Operating income
-$48.3M
Net income
-$65.8M
Gross margin
84.5%
Net margin
-39.5%
The gross profit has grown by 21% YoY and by 2.6% from the previous quarter
PRTK's revenue is up by 20% year-on-year and by 4% since the previous quarter
The operating income has declined by 19% year-on-year and by 4.5% since the previous quarter
PRTK's net income is down by 12% YoY and by 3.5% QoQ

Growth

What is Paratek Pharmaceuticals's growth rate over time

Valuation

What is Paratek Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.83
Paratek Pharmaceuticals's equity has decreased by 35% YoY and by 11% from the previous quarter
PRTK's price to sales (P/S) is 95% less than its 5-year quarterly average of 10.2 and 40% less than its last 4 quarters average of 0.9
PRTK's revenue is up by 20% year-on-year and by 4% since the previous quarter

Efficiency

How efficient is Paratek Pharmaceuticals business performance
Paratek Pharmaceuticals's ROA has decreased by 24% YoY and by 7% from the previous quarter
The ROIC has contracted by 10% YoY and by 6% from the previous quarter
The company's return on sales rose by 2.4% YoY

Dividends

What is PRTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTK.

Financial health

How did Paratek Pharmaceuticals financials performed over time
The total assets is 56% smaller than the total liabilities
PRTK's quick ratio is down by 33% YoY and by 17% QoQ
Paratek Pharmaceuticals's current ratio has decreased by 27% YoY and by 7% QoQ
Paratek Pharmaceuticals's equity has decreased by 35% YoY and by 11% from the previous quarter
The debt to equity has grown by 25% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.